

7. (Amended-Clean Text) The method of one of claim 1 wherein the nonionic surfactant is selected from the group consisting of polysorbate, polyoxeyethylenehydrogenated castor oil, and a poloxamer.

8. (Amended-Clean Text) The method of claim 1 wherein drying of the aqueous liquid is performed by spray drying, lyophilization or spray-freeze drying, or by coating which may be fluid-bed coating, or performed in fluid-bed granulation.

9. (Amended-Clean Text) The method of claim 1 wherein the average size of the particles making up the powder is 1-10 μm .

10. (Amended-Clean Text) The method of claim 1 wherein the physiologically active peptide is selected from the group consisting of growth hormones, insulins, calcitonins, erythropoietin, glucagon, somatostatin, somatostatin derivatives, interferons, interleukins, superoxide, dismutase, urokinase, proteases, tumor necrosis factors, colony-stimulating factors, kallikrein, lysozyme, fibronectin, insulin-like growth factors, epidermal growth factor, fibroblast growth factors, platelet-derived growth factor, nerve growth factor, hepatocyte growth factor, vasculogenesis factors and anti-vasculogenesis factors.

11. (Amended-Clean Text) The method of claim 1 wherein the physiologically active peptide is human growth hormone or human insulin.

12. (Amended-Clean Text) The method claim 1 wherein the physiologically active peptide is human growth hormone.

17. (Amended-Clean Text) The method for preparation of a powder containing a physiologically active peptide of claim 13 wherein the water-soluble, nonionic, organic binder is selected from the group consisting of polyvinylpyrrolidone, a water-soluble, nonionic cellulose derivative, and polyvinylalcohol.

19. (Amended-Clean Text) The method for preparation of a powder containing a physiologically active peptide of claim 13 wherein the nonionic surfactant is selected from the group consisting of polyisorbate, polyoxyethylenehydrogenated castor oil, and a poloxamer.

20. (Amended-Clean Text) The method for preparation of a powder containing a physiologically active peptide of claim 13 wherein drying of the aqueous liquid is performed by spray drying, lyophilization or spray-freeze drying, or by coating which may be fluid-bed coating, or performed in fluid-bed granulation.

21. (Amended-Clean Text) The method for preparation of a powder containing a physiologically active peptide of claim 13 wherein the average size of the particles making up the powder is 1-10 μm .

22. (Amended-Clean Text) The method for preparation of a powder containing a physiologically active peptide of claim 13 wherein the physiologically active peptide is selected from the group consisting of growth hormones, insulins, calcitonins, erythropoietin, glucagon, somatostatin, somatostatin derivatives, interferons, interleukins, superoxide,

GH cap
dismutase, urokinase, proteases, tumor necrosis factors, colony-stimulating factors, kallikrein, lysozyme, fibronectin, insulin-like growth factors, epidermal growth factor, fibroblast growth factors, platelet-derived growth factor, nerve growth factor, hepatocyte growth factor, vasculogenesis factors and anti-vasculogenesis factors.

23. (Amended-Clean Text) The method for preparation of a powder containing a physiologically active peptide of claim 13 wherein the physiologically active peptide is human growth hormone or human insulin.

24. (Amended-Clean Text) The method for preparation of a powder containing a physiologically active peptide of claim 13 wherein the physiologically active peptide is human growth hormone.

27. (Amended-Clean Text) The powder containing a physiologically active peptide of claim 25 wherein the average size of the particles is 1-10 μm .

GS
28. (Amended-Clean Text) The powder containing a physiologically active peptide of claim 25, for which drying of the aqueous liquid was performed by spray drying, spray-freeze drying, or lyophilization.

29. (Amended-Clean Text) The powder containing a physiologically active peptide of claim 25 wherein the physiologically active peptide is selected from the group consisting of growth hormones, insulins, calcitonins, erythropoietin, glucagon, somatostatin, somatostatin derivatives, interferons, interleukins, superoxide, dismutase, urokinase,

P20757:A01

proteases, tumor necrosis factors, colony-stimulating factors, kallikrein, lysozyme, fibronectin, insulin-like growth factors, epidermal growth factor, fibroblast growth factors, platelet-derived growth factor, nerve growth factor, hepatocyte growth factor, vasculogenesis factors and anti-vasculogenesis factors.

30. (Amended-Clean Text) The powder containing a physiologically active peptide of claim 25 wherein the physiologically active peptide is human growth hormone or human insulin.

31. (Amended-Clean Text) The powder containing a physiologically active peptide of claim 25 wherein the physiologically active peptide is human growth hormone.

32. (Amended-Clean Text) An inhalant composition containing a physiologically active peptide, wherein the inhalant composition comprises particles as defined in claim 25.


REMARKS

By the above amendment, the claims have been amended to delete multiple dependency.

P20757.A01

If there should be any questions, the Examiner is invited to contact the undersigned
at the telephone number listed below.

Respectfully submitted,
Yoshinobu HANYU et al.


Bruce H. Bernstein
Reg. No. 29,027

33,329

March 19, 2001
GREENBLUM & BERNSTEIN, P.L.C.
1941 Roland Clarke Place
Reston, VA 20191
(703) 716-1191